Search

Displaying results 2751 - 2760 of 10000 in total
  1. Drug

    Etuvetidigene Autotemcel

    go.drugbank.com/drugs/DB17593
    ApprovedInvestigational

    [A274878] The WAS protein is expressed on non-erythroid hematopoietic cells and regulates the function of actin filaments in the cytoskeleton.[A274878] … [L54698] First approved by the FDA on December 9, 2025, etuvetidigene autotemcel is used to treat Wiskott–Aldrich syndrome (WAS) in selected pediatric and adult patients.

  2. Drug

    Cycloserine

    go.drugbank.com/drugs/DB00260
    ApprovedInvestigational

    Antibiotic substance produced by Streptomyces garyphalus.

  3. Drug

    Guanethidine

    go.drugbank.com/drugs/DB01170
    ApprovedWithdrawn

    It is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues. … An antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves.

    Synonyms: 2-(1-N,N-Heptamethyleneimino)ethylguanidine, N-(2-Perhydroazocin-1-ylethyl)guanidine
  4. Drug

    Equine Botulinum Neurotoxin F Immune FAB2

    go.drugbank.com/drugs/DB13901
    Approved

    It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes F in adults and pediatric patients. … Equine Botulinum Neurotoxin F Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype F.

  5. Drug

    CX-052075

    go.drugbank.com/drugs/DB31655
    Approved

    [L53408] It is the primary ingredient in mNEXSPIKE, a COVID-19 mRNA vaccine developed by Moderna. … [L53413,A274083] mNEXSPIKE was approved by the US FDA in June 2025 for use in patients who have been previously vaccinated with any COVID-19 vaccine and who are at a higher risk of severe outcomes from

  6. Drug

    Pilocarpine

    go.drugbank.com/drugs/DB01085
    ApprovedInvestigational

    [A262016, A262036] Pilocarpine is associated with parasympathomimetic effects by selectively working on muscarinic receptors. … A naturally occurring alkaloid derived from the _Pilocarpus_ plants, pilocarpine is a muscarinic acetylcholine agonist.

  7. Drug

    Ansuvimab

    go.drugbank.com/drugs/DB16385
    Approved

    Infection with pathogenic filoviruses, such as _Zaire ebolavirus_ (Ebola virus, EBOV), can cause severe hemorrhagic fever in humans, resulting in frequent outbreaks with case fatality rates as high as … [A225943, A225948, A226035] A randomized, controlled trial of four investigational therapies for Ebola virus disease (EVD) in the Democratic Republic of Congo during a previous outbreak that began in 2018

  8. Drug

    Pinaverium

    go.drugbank.com/drugs/DB09090
    ApprovedInvestigational

    Pinaverium bromide is the common ingredient in formulations, mostly as oral tablets. … Although it is not a currently approved drug by the FDA, pinaverium is available in over 60 countries including Canada.

  9. Drug

    Teriflunomide

    go.drugbank.com/drugs/DB08880
    ApprovedInvestigational

    It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. … Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis.

  10. Drug

    Atenolol

    go.drugbank.com/drugs/DB00335
    ApprovedInvestigational

    Atenolol itself was developed early on in this history by Alvogen Malta under the trade name Tenormin and received FDA approval in September, 1981. … Atenolol is a cardioselective beta-blocker used in a variety of cardiovascular conditions.

    Products: MIN-T